Healthcare provider profile · identity verified

Meagan Ann Ducharme, APRN-C

Nurse Practitioner · TAMPA, FL · NPI 1881068310

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	438	62
Atorvastatin Calcium	Atorvastatin Calcium	316	49
Amlodipine Besylate	Amlodipine Besylate	248	45
Donepezil Hcl	Donepezil Hcl	228	29
Potassium Chloride	Potassium Chloride	205	38
Furosemide	Furosemide	190	32
Gabapentin	Gabapentin	188	30
Escitalopram Oxalate	Escitalopram Oxalate	176	30
Omeprazole	Omeprazole	169	25
Eliquis	Apixaban	167	25
Losartan Potassium	Losartan Potassium	156	33
Quetiapine Fumarate	Quetiapine Fumarate	145	25
Pantoprazole Sodium	Pantoprazole Sodium	142	29
Memantine Hcl	Memantine Hcl	112	21
Tamsulosin Hcl	Tamsulosin Hcl	111	17
Sertraline Hcl	Sertraline Hcl	108	21
Tramadol Hcl	Tramadol Hcl	108	26
Trazodone Hcl	Trazodone Hcl	108	22
Carvedilol	Carvedilol	103	15
Famotidine	Famotidine	97	15
Lisinopril	Lisinopril	95	20
Rosuvastatin Calcium	Rosuvastatin Calcium	83	14
Clopidogrel	Clopidogrel Bisulfate	79	13
Celecoxib	Celecoxib	78	12
Divalproex Sodium	Divalproex Sodium	77	suppressed
Montelukast Sodium	Montelukast Sodium	75	suppressed
Simvastatin	Simvastatin	72	13
Buspirone Hcl	Buspirone Hcl	68	suppressed
Metoprolol Succinate	Metoprolol Succinate	67	14
Mirtazapine	Mirtazapine	67	12
Alprazolam	Alprazolam	65	20
Methenamine Hippurate	Methenamine Hippurate	65	12
Metformin Hcl	Metformin Hcl	63	suppressed
Meloxicam	Meloxicam	62	17
Fluoxetine Hcl	Fluoxetine Hcl	55	suppressed
Latanoprost	Latanoprost	55	11
Hydrochlorothiazide	Hydrochlorothiazide	54	12
Oxybutynin Chloride	Oxybutynin Chloride	54	11
Metoprolol Tartrate	Metoprolol Tartrate	49	suppressed
Allopurinol	Allopurinol	48	suppressed
Citalopram Hbr	Citalopram Hydrobromide	47	suppressed
Lorazepam	Lorazepam	47	12
Spironolactone	Spironolactone	47	14
Bumetanide	Bumetanide	46	11
Levetiracetam	Levetiracetam	44	suppressed
Pregabalin	Pregabalin	44	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	43	suppressed
Atenolol	Atenolol	42	suppressed
Jardiance	Empagliflozin	42	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	42	34
Pravastatin Sodium	Pravastatin Sodium	41	suppressed
Amiodarone Hcl	Amiodarone Hcl	38	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	38	32
Finasteride	Finasteride	37	suppressed
Xarelto	Rivaroxaban	36	suppressed
Alendronate Sodium	Alendronate Sodium	33	suppressed
Propranolol Hcl	Propranolol Hcl	33	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	33	suppressed
Januvia	Sitagliptin Phosphate	32	suppressed
Glipizide Er	Glipizide	31	suppressed
Irbesartan	Irbesartan	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	29	suppressed
Cephalexin	Cephalexin	28	18
Baclofen	Baclofen	27	suppressed
Myrbetriq	Mirabegron	27	suppressed
Rybelsus	Semaglutide	27	suppressed
Clonazepam	Clonazepam	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Prednisone	Prednisone	25	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	19
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	suppressed
Nystatin	Nystatin	22	16
Risperidone	Risperidone	22	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Loperamide	Loperamide Hcl	20	13
Nifedipine Er	Nifedipine	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Methotrexate	Methotrexate Sodium	18	suppressed
Valsartan	Valsartan	18	suppressed
Calcitriol	Calcitriol	17	suppressed
Divalproex Sodium Er	Divalproex Sodium	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Mupirocin	Mupirocin	17	13
Nadolol	Nadolol	17	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	16	suppressed
Glipizide	Glipizide	16	suppressed
Metolazone	Metolazone	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Levofloxacin	Levofloxacin	14	14
Namzaric	Memantine Hcl/Donepezil Hcl	14	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	14	suppressed
Primidone	Primidone	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Nystop	Nystatin	13	suppressed
Anastrozole	Anastrozole	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Fluconazole	Fluconazole	12	11
Terazosin Hcl	Terazosin Hcl	12	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	12	suppressed
Trintellix	Vortioxetine Hydrobromide	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Ozempic	Semaglutide	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error